Vericiguat NEW
| Price | $40 | $106 | $147 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Vericiguat | CAS No.: 1350653-20-1 |
| Purity: 99.6% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Vericiguat |
| Description | Vericiguat (BAY1021189) is a potent and orally available guanylate cyclase stimulator. |
| In vitro | Vericiguat inhibits the U46619-induced contractions of porcine coronary artery rings concentration-dependently (IC50: 956 nM). Vericiguat inhibits phenylephrine-induced contractions of rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings concentration-dependently (IC50: 798, 692, and 3072 nM, respectively). Vericiguat (0.01 μM to 100 μM) stimulates recombinant sGC concentration-dependently, by 1.7-fold to 57.6-fold. When combined with the NO donor diethylamine/nitric oxide complex, Vericiguat and DEA/NO have a synergistic effect on the enzyme activity over a wide range of concentrations. At the highest concentrations of Vericiguat (100 μM) and DEA/NO (100 nM), the specific activity of sGC is 341.6-fold above baseline. Vericiguat stimulates the sGC reporter cell line concentration-dependently (EC50: 1005±145 nM) [1]. |
| In vivo | Vericiguat causes a significant and dose-dependent increase in survival rates. Chronic oral treatment with Vericiguat (3 or 10 mg/kg, q.d.) results in a significant attenuation of blood pressure increase during the course of the study. Vericiguat (3 or 10 mg/kg) treatment leads to a significant reduction in kidney injury molecule Kim-1 and osteopontin expression which are used as biomarkers for renal injury and dysfunction. In the 3 and 10 mg/kg q.d. treatment groups, the rat survival rate is 70% and 90%, respectively, at the study end [1]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (105.54 mM) |
| Keywords | Inhibitor | Vericiguat | inhibit | BAY 1021189 | Guanylate Cyclase | BAY-1021189 |
| Inhibitors Related | Methylene Blue | Methylene Blue trihydrate |
| Related Compound Libraries | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-12-18 | |
| $0.10/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-08-04 | |
| $0.00/1g |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2024-05-28 | |
| $0.00/1g |
VIP2Y
|
shandong perfect biotechnology co.ltd
|
2023-08-14 | |
| $0.00/1KG |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-07-17 | |
| $0.00/1KG |
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-14 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY